Christopher Palmer has been an associate editor at MDedge News since 2017. When he's not tidying grammar, he writes short pieces about breaking FDA announcements and approvals, as well as journal articles. He proudly holds a BA in English and philosophy. Follow him on Twitter @cmacmpalm.
News
FDA approves omadacycline for pneumonia and skin infections
The tetracycline antibiotic was approved for CABP and acute bacterial skin and skin structure infections in adults.
News
FDA approves Arikayce for MAC lung diseases
This is the first time a drug has been approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs.
News
Adalimumab safety update finds no new signals
The new integrated analysis includes safety data from five clinical trials that were not included in the analysis from 2009.
News
Burden of dementia will shift more to minorities by 2060
More culturally competent and appropriate interventions may be required.
News
FDA clears gold microparticles for acne vulgaris
These microparticles are designed to work with laser therapy to improve responses to treatment.
News
ICYMI: Canakinumab reduced risk of gout attacks
Previous analysis of CANTOS data showed canakinumab shortened the length of gout attacks.
News
FDA approves device for coronary artery perforations
This is the first device approved for acute coronary artery perforations in 17 years.
News
FDA grants praliciguat Fast Track Designation for HFpEF
Enrollment for a phase 2 trial in HFpEF patients continues.
News
Subcutaneous Actemra approved for systemic JIA
The safety profile was fairly similar to that seen with intravenous formulations.
News
Screen all infants exposed to Zika for eye abnormalities, study suggests
Although the correlation was high between CNS abnormalities and opthalmic abnormalities, there were exceptions.
News
FDA warns kratom vendors about unproven claims
The substance is already outlawed in several countries and banned in some states.
News
Regimens produce similar results in FL
Rituximab plus lenalidomide had efficacy similar to that of rituximab plus chemotherapy in the treatment of follicular lymphoma (FL) in a phase 3...